Urogen Pharma (URGN) Stock Statistics & Valuation Metrics

Urogen Pharma has a market cap or net worth of $1.41B. The enterprise value is $1.49B.

Urogen Pharma has 48,721,703 shares outstanding. The number of shares has decreased by -2.65% in one year.

Urogen Pharma’s return on equity (ROE) is 1.46 and return on invested capital (ROIC) is -81.06%.

The current PE Ratio of Urogen Pharma is ―. Urogen Pharma’s PEG ratio is -0.94.

In the last 12 months, Urogen Pharma had revenue of 109.79M and earned -153.49M in profits. Earnings per share was -3.19.

In the last 12 months, operating cash flow was -165.74M and capital expenditures -299.00K, giving a free cash flow of -166.03M billion.

Urogen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Urogen Pharma upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).

Urogen Pharma as a current ratio of 4.01, with Debt / Equity ratio of -158.62%

In the past 12 months, Urogen Pharma has paid 78.00K in taxes.

Urogen Pharma EV to EBITDA ratio is -8.44, with an EV/FCF ratio of -7.03.

Urogen Pharma has $141.60M in cash and marketable securities with $197.09M in debt, giving a net cash position of -$55.49M billion.

Gross margin is 89.85%, with operating margin of -113.73%, and net profit margin of -139.81%.

The average price target for Urogen Pharma is $36.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy